These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
17. Results of a multicenter prospective clinical study in Japan for evaluating efficacy and safety of desensitization protocol based on rituximab in ABO-incompatible kidney transplantation. Takahashi K; Saito K; Takahara S; Fuchinoue S; Yagisawa T; Aikawa A; Watarai Y; Yoshimura N; Tanabe K; Morozumi K; Shimazu M; Clin Exp Nephrol; 2017 Aug; 21(4):705-713. PubMed ID: 27534951 [TBL] [Abstract][Full Text] [Related]
18. Conversion of stable ABO-incompatible kidney transplant recipients from mycophenolate mofetil with standard exposure calcineurin inhibitors (CNIs) to everolimus with very low exposure CNIs-a short-term pilot study. Uchida J; Machida Y; Iwai T; Kuwabara N; Kabei K; Naganuma T; Kumada N; Kawashima H; Nakatani T Clin Transplant; 2014 Jan; 28(1):80-7. PubMed ID: 24329776 [TBL] [Abstract][Full Text] [Related]
19. Clinical outcomes of ABO-incompatible kidney transplant with rituximab and double-filtration plasmapheresis. Han S; Hwang E; Park S; Park U; Kim H; Cho W Exp Clin Transplant; 2014 Oct; 12(5):401-4. PubMed ID: 25299367 [TBL] [Abstract][Full Text] [Related]